Sandoz investor roadmap seen well-received as 2030 guidance set
Vontobel’s Stefan Schneider said Sandoz’s years-ahead roadmap is likely to be well received after it confirmed a 2028 outlook, set new 2030 guidance ahead of Vontobel estimates, and projected an acceleration.
Sandoz Group’s roadmap for the years ahead is likely to be well received by investors, Vontobel’s Stefan Schneider said in a research note. The Swiss maker of generic medicines confirmed its 2028 outlook and set out new 2030 guidance that is ahead of Vontobel’s estimates, and projected an acceleration…